Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rethinking Molecular Profiling after First-line Osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2026

Gupta Komal, Tan Daniel S W, Hoo Regina

Abstract excerpt

A recent article presents the largest histogenomic characterization of first-line osimertinib resistance from the ORCHARD study. Dual-modality tissue and plasma sequencing detected resistance alterations in 87% of patients and polyclonal mechanisms in 46% of patients, highlighting the complexity of post-osimertinib biology and raising questions about targeted versus broadly acting regimens in the post-EGFR...

Read the complete abstract on PubMed

Topics

Humans
Pyrimidines
Aniline Compounds
Acrylamides
Indoles
Drug Resistance, Neoplasm
Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Mutation

ErbB Receptors

Antineoplastic Agents

Source

Identifiers

PMID: 42430304
DOI: 10.1158/1078-0432.CCR-26-0749

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rethinking Molecular Profiling after First-line Osimertinib.PMID 42430304Read ↗

Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study.Semantic proximity Read ↗

Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.Semantic proximity Read ↗

Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.Semantic proximity Read ↗

EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcomeSemantic proximity Read ↗

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.Semantic proximity Read ↗

Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.Semantic proximity Read ↗

Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.Semantic proximity Read ↗

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).Semantic proximity Read ↗

Patients with uncommon EGFR mutations also benefit from first-line osimertinib.Semantic proximity Read ↗

ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.Semantic proximity Read ↗

Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.Semantic proximity Read ↗

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.